ESMO E-Learning: Thoracic Oncology Highlights 2014

Learning Objectives

  • To provide a general update on new developments in the treatment of patients with local/locally advanced and recurrent/metastatic non-small cell lung cancer (NSCLC), as well as patients with extensive stage SCLC.
  • To provide an update on the latest clinical research findings in lung tumours with targetable oncogenic driver alterations, new options for second-line therapy, and promising emerging immunotherapy approaches. 
  • To view clinically meaningful findings from a treatment perspective.
Title Duration Content CME Points CME Test
Thoracic Oncology Highlights 2014 36 min. 47 slides 1 Take Test
Reck-Martin
Martin Reck
Read more
Reinmuth-Niels
Niels Reinmuth
Read more

The oncology community is currently being faced with a number of significant results from lung cancer clinical trials, mainly in patients with non-small cell lung cancer (NSCLC) histology types. The aim of this E-Learning module is to summarise from the clinical perspective some of the most important results in NSCLC presented at the main oncology events in 2014. In addition, some of the noteworthy clinical advances that have been presented in 2015 (which will be fully covered in a subsequent module) will be introduced.

This module consists of three parts: the first part is focused on local/locally advanced NSCLC; the second part on recurrent/metastatic NSCLC, and the third part on extensive stage SCLC

In the first part the authors describe the results from the following studies on local/locally advanced NSCLC:

  • The RADIANT phase III trial of adjuvant erlotinib following complete tumour resection with or without adjuvant chemotherapy in patients with stage IB-IIIA NSCLC.
  • The SELECT study, a multicentre phase II trial of adjuvant erlotinib in resected early-stage EGFR mutation-positive NSCLC.
  • The MAGRIT study of adjuvant immunotherapy in patients with resected MAGE-A3-positive NSCLC.

In the second part of the module, dedicated to recurrent/metastatic NSCLC, the authors begin by describing the results from:

The PROFILE 1014 study of first-line crizotinib versus pemetrexed-cisplatin in patients with advanced ALK-positive non-squamous NSCLC. They then discuss a pooled analysis of two phase III studies in patients with EGFR-mutated advanced NSCLC, comparing afatinib with standard chemotherapy. They also analyse the data from first-line erlotinib plus bevacizumab versus erlotinib alone in advanced EGFR mutation-positive non-squamous NSCLC. In squamous cell NSCLC, results from the SQUIRE study of cisplatin/gemcitabine plus necitumumab are discussed.

In terms of Antiangiogenic treatment, results from the REVEL study of docetaxel plus ramucirumab in the second-line treatment of stage IV NSCLC are presented. Regarding immunotherapy, the authors present results from the KEYNOTE-001 study, analysing pembrolizumab and the correlation with PD-L1 expression in advanced NSCLC, and results from the Checkmate 063 study of nivolumab in squamous NSCLC after at least two prior systemic regimens. 

Finally, in the third part of the module, the authors present data from studies in extensive stage SCLC, including a randomised trial on thoracic radiotherapy and a randomised phase III study of prophylactic cranial irradiation.

The authors cover the mechanisms and key pathways implicated in activity for all the agents mentioned above and also provide key efficacy results and safety profiles. 

For anyone who has missed any information from lung cancer studies presented last year, this E-Learning module is the perfect and easiest way to keep up-to-date with the latest clinical highlights in thoracic oncology.

Last update: 01 December 2015

Prof Reck has reported to have received honoraria for consultation and lectures from Hoffmann-La Roche, Lilly, Bristol-Myers Squibb, AstraZeneca, MSD, Pfizer, Novartis, Boehringer-Ingelheim.

Prof Reinmuth has reported to be part of Speaker’s bureau at Hoffmann-La Roche, Lilly, Novartis, Boehringer-Ingelheim, TEVA, Otsuka, MSD and Bristol-Myers Squibb.